Development of an Algorithm to Differentiate Heart Murmurs Using Electronic Stethoscopes
NCT ID: NCT04400513
Last Updated: 2023-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1145 participants
OBSERVATIONAL
2020-06-25
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improvement of an Algorithm to Detect Structural Heart Murmurs in Adult Patients Using Electronic Stethoscopes
NCT07202104
Detection of Heart Conditions Using Artificial Intelligence
NCT04933890
Real-World Evaluation of Eko Murmur Analysis Software in a Point of Care Setting
NCT05176899
Real-World Evaluation of Eko Algorithms in a Point of Care Setting
NCT05459545
Heart Failure Monitoring With Eko Electronic Stethoscopes
NCT04404452
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
AS, mitral regurgitation (MR), and tricuspid regurgitation (TR) all result in reliably reproducible auscultatory findings. Yet despite this, auscultation as a diagnostic procedure is notoriously poor: its accuracy to detect AS, MR, and TR ranges only from 5-40%. In addition, diastolic and continuous murmurs, which are rarer than the systolic murmurs caused by AS, MR and TR, and almost always pathologic, are usually very difficult to detect by frontline clinicians. Diastolic murmurs are typically caused by VHD such as aortic regurgitation (AR), pulmonic regurgitation (PR), mitral stenosis (MS), or tricuspid stenosis (TS), and continuous murmurs are typically caused by non-valvular forms of SHD, such as congenital aortopulmonary window, shunts, and patent ductus arteriosus (PDA). Missing one of these murmurs could lead to significantly delayed diagnosis and care.
Because of how difficult it is for clinicians to reliably screen for SHD through history taking and physical examination, the diagnosis of SHD relies heavily on echocardiography (echos), which is accepted as the gold standard for diagnosis of SHD severity by the cardiology community. The consequence of this is several-fold. First, many patients receive echos that would not be necessary if better screening and assessment tools existed. Second, echocardiography makes up a disproportionately large segment of healthcare expenditure. Third, patients are burdened with the responsibility of getting repeated echos due to the lack of better screening tools. The emotional, physical, and financial burden that accompanies such excessive testing, especially for patients living in underserved communities, cannot be overstated.
Overall, there is a growing need for better preliminary screening tools that would identify these conditions, even when asymptomatic, early on and more consistently, to a degree of accuracy comparable to gold standard echocardiography. Such a tool would improve clinicians' confidence in their assessment during physical exams, which would enable them to help their patients make informed care decisions, offer disease-altering therapies, and at the same time reduce the reliance on, and frequency of, unnecessary and expensive auxiliary workups. Lastly, by facilitating early detection of VHD, morbidity and mortality rates would be expected to decrease due to earlier intervention.
The FDA-approved Eko CORE and Eko DUO electronic stethoscopes offer clinicians a familiar and inexpensive tool that is widely accepted by patients, while at the same time offer sensors and technology that can improve screening and detection of medical conditions such as valve disease, as compared to auscultation with the traditional stethoscope. Both CORE and DUO feature sound amplification during auscultation, which improves the ability for the clinician to detect nuanced changes in heart sounds and patterns. The CORE allows recording of the audio to produce a phonocardiogram (PCG), while the DUO is able to record audio to produce a PCG as well as simultaneous recording of a single-lead electrocardiogram (ECG). Both devices use Bluetooth to wirelessly transmit PCG and ECG data to the Eko mobile application, which allows clinicians to visualize PCG and ECG as they auscultate, as well as to playback heart sound recordings, annotate notes on recorded audio, and save and share recordings. These features uniquely situate Eko electronic stethoscopes to be highly effective as preliminary screening tools in clinical practice.
Eko Devices has developed and received 510(k) FDA approval for a machine-learning (ML) algorithm that can detect the presence or absence of heart murmur in adult patients with VHD, using either the Eko CORE or DUO electronic stethoscopes to record heart sounds. This algorithm was built using a deep neural network model trained on 5,878 PCG recordings collected on Eko CORE and Eko DUO from over 5,318 unique patients to classify heart sound recordings as containing a heart murmur or containing no audible murmur, and to discriminate good quality heart sound recordings from poor quality heart sound recordings. The trained model has been independently validated in a multi-site clinical study that enrolled 681 VHD patients with matched gold-standard echocardiograms. FDA approval was received in January 2020.
The present study seeks to expand murmur detection to include VHD classification through the development of novel ML algorithms that are able to distinguish between systolic vs. diastolic vs. continuous murmurs, as well as classify VHD type and severity, using 4-point auscultation with Eko CORE and DUO electronic stethoscopes to record heart sounds. These new algorithms will integrate the time-synchronized ECG streams from DUO to improve distinction between S1 and S2 heart sounds and improve performance of identifying systolic vs. diastolic time intervals. When combined with the FDA-approved algorithm for signal quality and murmur detection, these new algorithms will enable clinicians to have a complete VHD decision support system, as based on ACC/AHA Patient Management Guidelines, when using Eko stethoscopes in their clinical practice.20 This will arm clinicians with information to help them detect SHD early, make clinical care decisions with confidence and consistency, and improve overall patient outcomes while decreasing cost and increasing efficiency.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aortic Stenosis
Subjects with echo-confirmed AS graded moderate-to-severe or worse
Use of Eko CORE and Eko DUO electronic stethoscopes
Auscultation of heart sounds using electronic stethoscopes
Mitral Regurgitation
Subjects with echo-confirmed MR graded moderate-to-severe or worse
Use of Eko CORE and Eko DUO electronic stethoscopes
Auscultation of heart sounds using electronic stethoscopes
Tricuspid Regurgitation
Subjects with echo-confirmed TR graded moderate-to-severe or worse
Use of Eko CORE and Eko DUO electronic stethoscopes
Auscultation of heart sounds using electronic stethoscopes
Innocent Murmur
Subjects with echo-confirmed trace/trivial valve disease severity
Use of Eko CORE and Eko DUO electronic stethoscopes
Auscultation of heart sounds using electronic stethoscopes
Diastolic Murmur
Subjects with pathology associated with diastolic murmur (e.g. AR, PR, MS, TS)
Use of Eko CORE and Eko DUO electronic stethoscopes
Auscultation of heart sounds using electronic stethoscopes
Continuous Murmur
Subjects with pathology associated with continuous murmur (e.g. congenital shunts, PDA)
Use of Eko CORE and Eko DUO electronic stethoscopes
Auscultation of heart sounds using electronic stethoscopes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Use of Eko CORE and Eko DUO electronic stethoscopes
Auscultation of heart sounds using electronic stethoscopes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient or patient's legal healthcare proxy consents to participation
3. Have an audible heart murmur in at least one auscultation position, as heard by a clinician
4. Undergoing or have undergone a complete (i.e., not limited) echocardiogram
5. Willing to have heart recordings done with two different electronic stethoscopes
Exclusion Criteria
2. Unable to complete a full clinical echocardiogram
3. No audible heart murmur in at least one auscultation position, as heard by a clinician
4. Experiencing a known or suspected acute cardiac event
5. Mechanical ventricular support (such as ECMO, LVAD, RVAD, BiVAD, Impella, intra-aortic balloon pumps, TAH, VentrAssist, DuraHeart, HVAD, EVAHEART LVAS, HeartMate, Jarvik 2000)
6. Unwilling or unable to follow or complete study procedures
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eko Devices, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CoxHealth
Springfield, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020.3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.